Who are Maintenance of alpha-blocker and 5-ARI's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/maintenance-of-alpha-blocker-and-5-ari.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Maintenance of alpha-blocker and 5-ARI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maintenance of alpha-blocker and 5-ARI (Maintenance of alpha-blocker and 5-ARI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-blocker and 5-alpha reductase inhibitor combination. Area: Urology.

phase 3 Alpha-blocker and 5-alpha reductase inhibitor combination Alpha-1 adrenergic receptor and 5-alpha reductase enzyme Urology Small molecule Live · refreshed every 30 min

Target snapshot

Maintenance of alpha-blocker and 5-ARI (Maintenance of alpha-blocker and 5-ARI) — Gangnam Severance Hospital. This combination therapy maintains symptom relief in benign prostatic hyperplasia by combining alpha-blocker-mediated smooth muscle relaxation with 5-alpha reductase inhibitor-mediated reduction of prostate volume.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Maintenance of alpha-blocker and 5-ARI TARGET	Maintenance of alpha-blocker and 5-ARI	Gangnam Severance Hospital	phase 3	Alpha-blocker and 5-alpha reductase inhibitor combination	Alpha-1 adrenergic receptor and 5-alpha reductase enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-blocker and 5-alpha reductase inhibitor combination class)

Gangnam Severance Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Maintenance of alpha-blocker and 5-ARI — Competitive Intelligence Brief. https://druglandscape.com/ci/maintenance-of-alpha-blocker-and-5-ari. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab